Cue Biopharma, Inc. (CUE) financial statements and ratios from SEC XBRL: revenue $27.47M (TTM), net margin -96.9%, revenue growth 166.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $27.47M |
| Net Margin | -96.9% |
| Revenue Growth (YoY) | 166.7% |
| EPS Growth (YoY) | 26722.2% |
| FCF Growth (YoY) | 742.6% |
| Price / Book | 75.35 |
| Price / Sales | 4.62 |
| FCF Yield | -28.8% |
| Altman Z-Score | 75.99 (safe) |
| Sector P/E (Healthcare) | 21.7 |
CUE overview · CUE earnings · CUE KPIs · CUE investor relations · CUE ownership · CUE peers · CUE filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.